US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.55

+0.01950.16%

Volume:94.13K

Turnover:1.18M

Market Cap:693.42M

PE:10.64

High:12.55

Open:12.53

Low:12.51

Close:12.53

52wk High:13.59

52wk Low:12.50

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.16

T/O Rate:0.17%

Dividend:1.42

Dividend Rate:11.28%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.87

PE(LYR):- -

Loading ...

Overview Company News Filings

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Brookfield Real Assets Income Fund announces annual shareholder meeting

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Brookfield Real Assets Income Fund updates distribution schedule; monthly payout holds at $0.1180 per share for Q2 2026

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase

Press Release: Equillium Announces $35 Million Financing with RA Capital Management

Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts

Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating

Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Brookfield Real Assets Income Fund to Lose Co-Portfolio Manager Paula Horn on June 30, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/RA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.5495,"timestamp":1788454338160,"preClose":12.53,"halted":0,"volume":94132,"delay":0,"changeRate":0.0015562649640862521,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Trading","change":0.0195,"latestTime":"09-03 12:52:40 EDT","open":12.53,"high":12.55,"low":12.5101,"amount":1179548.700808,"amplitude":0.003184,"askPrice":12.55,"askSize":200,"bidPrice":12.51,"bidSize":60,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.53,"dividendRate":0.112785,"preHourTrading":{"tag":"盘前","latestPrice":12.55,"preClose":12.53,"latestTime":"09:16 EDT","volume":86,"amount":1079.37998,"timestamp":1788441412696,"change":0.02,"changeRate":0.001596,"amplitude":0.005587},"postHourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.53,"latestTime":"19:30 EDT","volume":26,"amount":326.0014,"timestamp":1788391808982,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.157254},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.157254,"shares":55254696,"dividePrice":1.4154,"high":12.55,"amplitude":0.003184,"preClose":12.53,"low":12.5101,"week52Low":12.5,"pbRate":"0.87","week52High":13.59,"institutionHeld":0,"latestPrice":12.5495,"committee":-0.538462,"eps":1.18,"divideRate":0.112785,"volume":94132,"delay":0,"ttmEps":1.18,"open":12.53,"prevYearClose":12.96,"prevWeekClose":12.62,"prevMonthClose":12.55,"prevQuarterClose":12.88,"fiveDayClose":12.63,"twentyDayClose":12.77,"sixtyDayClose":12.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633437715","title":"Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437715","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437715?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":"Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3290957/0/en/Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-i.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B7SZL793.SGD","CRS","LU2065731478.USD","IE00B66KJ199.SGD","LU0963586101.USD","RA","LABU","IE0031619046.USD","BK4187","IE00B19Z4B17.USD","BK4006","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","RA","SLE","BK4139","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BP","ATS","IBD","BK4588","BK4132","BPH","LU0320765646.SGD","LU1162221912.USD","LU0162691827.USD","BK4006","SID","BK4139","EASI","BK4096","PN","BK4201","LU1829250122.USD","BK4161","AD","LU0006061336.USD","LU0072461881.USD","RA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627745208","title":"Brookfield Real Assets Income Fund announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627745208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627745208?lang=en_us&edition=fundamental","pubTime":"2026-04-14 00:41","pubTimestamp":1776098468,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund set May 21, 2026, for virtual annual shareholder meeting.Shareholders will vote on election of Class I directors.Board nominees include Brian F. Hurley as interested director, Betty A. Whelchel as independent director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL3RFkLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","AS","BK7050","BK4099","LU1223082196.USD","ZK","CDE.AU","CDE","RA","LU1223083913.SGD","LU1223082519.USD","BK4202","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625732914","title":"RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625732914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625732914?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:19","pubTimestamp":1775639978,"startTime":"0","endTime":"0","summary":"The latest update is out from United Co RUSAL ( ($HK:0486) ). United Company RUSAL has disclosed that its BO-001P-16 series exchange-traded bonds, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623865317","title":"Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623865317","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623865317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872060,"startTime":"0","endTime":"0","summary":"First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjgren’s disease $75 million private placement strengthens balance sheet and supports telitacicep","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264589/0/en/Vor-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317889","title":"Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317889","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317889?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"First and only dual BAFF/APRIL inhibitor in primary Sjgren’s disease, one of the largest autoimmune diseases without an approved therapyBOSTON, March  30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264556/0/en/Vor-Bio-Doses-First-Patient-in-Global-Phase-3-UPSTREAM-SjD-Registrational-Trial-of-Telitacicept-in-Primary-Sj%C3%B6gren-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622742803","title":"Brookfield Real Assets Income Fund updates distribution schedule; monthly payout holds at $0.1180 per share for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622742803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622742803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:15","pubTimestamp":1774646158,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund set monthly distributions of USD 0.12 per share for April 2026, with a record and ex-dividend date of April 9, 2026 and a payable date of April 23, 2026.May 2026 distribution of USD 0.12 per share has a record and ex-dividend date of May 7, 2026 and a payable date of May 21, 2026.June 2026 distribution of USD 0.12 per share has a record and ex-dividend date of June 11, 2026 and a payable date of June 25, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL869Lpq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B3QW5Z07.USD","SG9999014021.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","RA","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896695","title":"Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896695","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896695?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:02","pubTimestamp":1774555320,"startTime":"0","endTime":"0","summary":"Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026  Progressing enrollment for","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263388/0/en/Kyverna-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LD","BK4588","BK4023","BK4178","BK4006","IE0031619046.USD","HCP","IE00B19Z4B17.USD","KYTX","BK4187","IND","BK4139","BK4585","CRS","CAR","IE00B66KJ199.SGD","ACR","BK4230","RA","LU0963586101.USD","LU2065731478.USD","BK4110","IE00B7SZL793.SGD","AAN","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620622238","title":"SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2620622238","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620622238?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:38","pubTimestamp":1773819480,"startTime":"0","endTime":"0","summary":"The latest announcement is out from SynAct Pharma AB ( ($SE:SYNACT) ). SynAct Pharma will present and hold partnering meetings at the BIO-Europe Sp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/synact-pharma-targets-ra-partnerships-with-bio-europe-spring-2026-showcase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/synact-pharma-targets-ra-partnerships-with-bio-europe-spring-2026-showcase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4085","LU2238330802.EUR","BIO","LU0737861269.HKD","LU0572940350.SGD","BK4220","LU0072462343.USD","LU1861217088.USD","BK4588","SG9999013460.SGD","BK4551","LU1242518857.USD","LU1048588211.SGD","BK4566","LU2125910500.SGD","SGXZ58947870.SGD","SG9999013486.USD","LU0264606111.USD","LU0289960550.SGD","LU0979878070.USD","LU0516422440.USD","LU0823039010.USD","LU2177674079.SGD","LU0348788117.USD","LU0210637038.USD","LU1169590202.USD","LU0532188223.SGD","SG9999005177.SGD","LU0516422366.SGD","LU1169589451.USD","LU1242518931.SGD","LU0251143029.SGD","LU2152927971.USD","LU2543165471.USD","LU0499858602.USD","BK4535","LU1861220207.SGD","LU2125910849.SGD","LU0516423174.USD","RA","SG9999006266.SGD","LU2065171311.SGD","LU2008162690.USD","SG9999002406.SGD","LU0441851309.USD","IE0034224299.USD","LU0499858438.USD","BK4121","SG9999001135.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194132","title":"Press Release: Equillium Announces $35 Million Financing with RA Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194132","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194132?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403200,"startTime":"0","endTime":"0","summary":"Capital strengthens the advancement of EQ504 through key clinical milestones. Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029. Pursuant to the terms of the securities purchase agreement, the Company will issue approximately 18.9 million shares of its common stock , representing a purchase price of $1.854 for each share of common stock  or $1.8539 for each pre-funded warrant sold in lieu of common stock at closing. Gross proceeds from the financing are expected to be $35 million, before deducting expenses.The offer and sale of the foregoing securities to be issued in the PIPE financing are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended , or any applicable state securities laws.  Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption fr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ","RA","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618535949","title":"Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2618535949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618535949?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:55","pubTimestamp":1773226528,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum of Needham maintained a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $18.00. Gil Blum has given his Buy rati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-sufficient-cash-runway-to-2027-supports-buy-rating-ahead-of-key-2026-ra-efficacy-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-sufficient-cash-runway-to-2027-supports-buy-rating-ahead-of-key-2026-ra-efficacy-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618946600","title":"Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946600","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946600?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:35","pubTimestamp":1773225350,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ARTV stock, giving a Buy rating yesterday. Emily Bodnar has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-de-risking-ra-opportunity-with-allonk-and-fast-track-path-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-de-risking-ra-opportunity-with-allonk-and-fast-track-path-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618966465","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966465","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966465?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:05","pubTimestamp":1773173100,"startTime":"0","endTime":"0","summary":"Initial clinical response data for AlloNK in refractory rheumatoid arthritis  expected in first half of 2026. U.S. Food and Drug Administration  interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026. Strengthened board and executive leadership with deep immunology, commercial and financial expertise. Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027. Dr. Aslan continued, \"In 2026, our focus is to advance AlloNK from an early clinical program in the deep B-cell depletion space to what could become the first therapy in this class to initiate a registrational trial in RA, the autoimmune disease with the largest refractory population. We look forward to sharing initial clinical response data and engaging with the FDA on a potential pivotal trial design in refractory RA in the first half of 2026.\". -- Prioritized refractory RA as lead indication: Recei","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4077","BK4187","CRS","IE0031619046.USD","RA","IE00B19Z4B17.USD","R","ARTV","SLE","IE00B7SZL793.SGD","BK4022","LU2065731478.USD","IE00B66KJ199.SGD","BK4006","BK4232","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618243934","title":"Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618243934","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618243934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252628/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","SLE","BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617035630","title":"Brookfield Real Assets Income Fund to Lose Co-Portfolio Manager Paula Horn on June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617035630","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617035630?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:06","pubTimestamp":1772831174,"startTime":"0","endTime":"0","summary":"Brookfield Public Securities Group LLC said Brookfield Real Assets Income Fund Inc. will change its portfolio management team effective June 30, 2026, as Paula Horn steps down as co-portfolio manager. Co-portfolio managers Gaal Surugeon, Chris Janus and Riley O'Neil will continue to oversee allocation decisions for the fund.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL883Vqq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014039.USD","BK4135","SG9999014021.USD","IE00B775SV38.USD","SG9999014013.SGD","LU2095319765.USD","BK4112","LU0314104364.USD","RA","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3S45H60.SGD","BK4588","LU2210150020.SGD","BN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}]}}